RU2014102938A - Композиция вакцины для трансдермального введения - Google Patents
Композиция вакцины для трансдермального введения Download PDFInfo
- Publication number
- RU2014102938A RU2014102938A RU2014102938/10A RU2014102938A RU2014102938A RU 2014102938 A RU2014102938 A RU 2014102938A RU 2014102938/10 A RU2014102938/10 A RU 2014102938/10A RU 2014102938 A RU2014102938 A RU 2014102938A RU 2014102938 A RU2014102938 A RU 2014102938A
- Authority
- RU
- Russia
- Prior art keywords
- agonist
- receptor
- receptor agonist
- inhibitor
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 20
- 229960005486 vaccine Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 claims abstract 15
- 229940022399 cancer vaccine Drugs 0.000 claims abstract 13
- 239000000556 agonist Substances 0.000 claims abstract 10
- 230000007969 cellular immunity Effects 0.000 claims abstract 7
- 230000006698 induction Effects 0.000 claims abstract 7
- 229940044601 receptor agonist Drugs 0.000 claims abstract 7
- 239000000018 receptor agonist Substances 0.000 claims abstract 7
- 239000002253 acid Substances 0.000 claims abstract 5
- AHOKKYCUWBLDST-QYULHYBRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=CC=C1 AHOKKYCUWBLDST-QYULHYBRSA-N 0.000 claims abstract 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims abstract 4
- 101800000324 Immunoglobulin A1 protease translocator Proteins 0.000 claims abstract 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims abstract 4
- 229930195712 glutamate Natural products 0.000 claims abstract 4
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 claims abstract 3
- 108090000695 Cytokines Proteins 0.000 claims abstract 3
- 102000004127 Cytokines Human genes 0.000 claims abstract 3
- 229940098778 Dopamine receptor agonist Drugs 0.000 claims abstract 3
- 229940121909 GABA receptor agonist Drugs 0.000 claims abstract 3
- 229940123322 Histamine receptor agonist Drugs 0.000 claims abstract 3
- 229940122236 Histamine receptor antagonist Drugs 0.000 claims abstract 3
- 229940121723 Melatonin receptor agonist Drugs 0.000 claims abstract 3
- 229940118169 Prostaglandin receptor agonist Drugs 0.000 claims abstract 3
- 229940122144 Prostaglandin receptor antagonist Drugs 0.000 claims abstract 3
- 229940121846 Sphingosine 1-phosphate receptor agonist Drugs 0.000 claims abstract 3
- 239000000739 antihistaminic agent Substances 0.000 claims abstract 3
- 229940121376 cannabinoid receptor agonist Drugs 0.000 claims abstract 3
- 239000003537 cannabinoid receptor agonist Substances 0.000 claims abstract 3
- 125000004122 cyclic group Chemical group 0.000 claims abstract 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims abstract 3
- 229940079593 drug Drugs 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 3
- 239000003453 histamine agonist Substances 0.000 claims abstract 3
- 230000002519 immonomodulatory effect Effects 0.000 claims abstract 3
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims abstract 3
- 239000003789 leukotriene receptor stimulating agent Substances 0.000 claims abstract 3
- 239000003446 ligand Substances 0.000 claims abstract 3
- 239000002089 prostaglandin antagonist Substances 0.000 claims abstract 3
- 239000002522 prostaglandin receptor stimulating agent Substances 0.000 claims abstract 3
- 239000000952 serotonin receptor agonist Substances 0.000 claims abstract 3
- 229940106049 Angiotensin agonist Drugs 0.000 claims abstract 2
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 claims abstract 2
- 229940121891 Dopamine receptor antagonist Drugs 0.000 claims abstract 2
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 claims abstract 2
- 229940121743 Muscarinic receptor agonist Drugs 0.000 claims abstract 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims abstract 2
- 108010014865 PLIalpha Proteins 0.000 claims abstract 2
- 229940126033 PPAR agonist Drugs 0.000 claims abstract 2
- 229940123898 Phospholipase A2 inhibitor Drugs 0.000 claims abstract 2
- 108050001286 Somatostatin Receptor Proteins 0.000 claims abstract 2
- 102000011096 Somatostatin receptor Human genes 0.000 claims abstract 2
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims abstract 2
- 102000004136 Vasopressin Receptors Human genes 0.000 claims abstract 2
- 108090000643 Vasopressin Receptors Proteins 0.000 claims abstract 2
- 239000000048 adrenergic agonist Substances 0.000 claims abstract 2
- 239000000674 adrenergic antagonist Substances 0.000 claims abstract 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims abstract 2
- 239000003420 antiserotonin agent Substances 0.000 claims abstract 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims abstract 2
- 239000003210 dopamine receptor blocking agent Substances 0.000 claims abstract 2
- 229940049906 glutamate Drugs 0.000 claims abstract 2
- 239000003514 metabotropic receptor agonist Substances 0.000 claims abstract 2
- 239000000472 muscarinic agonist Substances 0.000 claims abstract 2
- 239000003149 muscarinic antagonist Substances 0.000 claims abstract 2
- 229940012843 omega-3 fatty acid Drugs 0.000 claims abstract 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract 2
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 claims abstract 2
- 239000003358 phospholipase A2 inhibitor Substances 0.000 claims abstract 2
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims abstract 2
- 229940121356 serotonin receptor antagonist Drugs 0.000 claims abstract 2
- 230000023750 transforming growth factor beta production Effects 0.000 claims abstract 2
- 239000002536 vasopressin receptor antagonist Substances 0.000 claims abstract 2
- 230000007794 irritation Effects 0.000 claims 4
- 239000012790 adhesive layer Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 230000023441 thymic stromal lymphopoietin production Effects 0.000 claims 2
- 229940122658 Adenylate cyclase inhibitor Drugs 0.000 claims 1
- 108010064733 Angiotensins Proteins 0.000 claims 1
- 102000015427 Angiotensins Human genes 0.000 claims 1
- 102000015554 Dopamine receptor Human genes 0.000 claims 1
- 108050004812 Dopamine receptor Proteins 0.000 claims 1
- 102100037600 P2Y purinoceptor 1 Human genes 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims 1
- 108010085249 Purinergic P2 Receptors Proteins 0.000 claims 1
- 206010040880 Skin irritation Diseases 0.000 claims 1
- 229940123051 Somatostatin receptor agonist Drugs 0.000 claims 1
- 229940117028 Thrombin receptor agonist Drugs 0.000 claims 1
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 claims 1
- 239000002390 adhesive tape Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000036556 skin irritation Effects 0.000 claims 1
- 231100000475 skin irritation Toxicity 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000003856 thrombin receptor antagonist Substances 0.000 claims 1
- OXHYRVSBKWIFES-WWSDOYNLSA-N trap-14 peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=CC=C1 OXHYRVSBKWIFES-WWSDOYNLSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013020799 | 2013-02-05 | ||
| JP2013-020799 | 2013-02-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014102938A true RU2014102938A (ru) | 2015-08-10 |
Family
ID=50028736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014102938/10A RU2014102938A (ru) | 2013-02-05 | 2014-01-29 | Композиция вакцины для трансдермального введения |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20140220100A1 (enExample) |
| EP (1) | EP2762158A1 (enExample) |
| JP (1) | JP2014169278A (enExample) |
| KR (1) | KR20140100415A (enExample) |
| CN (1) | CN103961696A (enExample) |
| CA (1) | CA2840997A1 (enExample) |
| IN (1) | IN2014CH00390A (enExample) |
| RU (1) | RU2014102938A (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2841014A1 (en) | 2013-02-05 | 2014-08-05 | Nitto Denko Corporation | Tape preparation of wt1 peptide cancer vaccine for transdermal administration |
| CN103961307B (zh) | 2013-02-05 | 2019-11-29 | 日东电工株式会社 | 经皮给予用wt1肽癌症疫苗组合物 |
| TW201618790A (zh) * | 2014-10-02 | 2016-06-01 | Nitto Denko Corp | 經皮投與用疫苗醫藥組合物 |
| US20230233480A1 (en) * | 2019-10-24 | 2023-07-27 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system for the transdermal administration of fingolimod |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
| US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| IL127331A0 (en) | 1998-11-30 | 1999-09-22 | Yeda Res & Dev | Peptide-based vaccine for influenza |
| EP1377299A4 (en) * | 2001-03-19 | 2009-11-11 | Intercell Usa Inc | TRANSCUTANE IMMUNOSTIMULATION |
| US20050215501A1 (en) * | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
| WO2005089777A1 (en) | 2004-03-15 | 2005-09-29 | Karaolis David K R | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| DE102004049223A1 (de) | 2004-10-08 | 2006-04-20 | Johannes-Gutenberg-Universität Mainz | Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung |
| CA2523032A1 (en) * | 2005-10-07 | 2007-04-07 | Immunovaccine Technologies Inc. | Vaccines for cancer therapy |
| WO2008011672A1 (en) * | 2006-07-25 | 2008-01-31 | 4G Vaccines Pty Ltd | A cancer vaccine comprising a mucin 1 (muc1) t cell epitope-derived peptide |
| US20080112974A1 (en) | 2006-09-08 | 2008-05-15 | Duotol Ab | Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens |
| EP2162149B1 (en) * | 2007-06-01 | 2013-11-06 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Vaccine for the prevention of breast cancer relapse |
| US9764012B2 (en) * | 2009-04-01 | 2017-09-19 | University Of Miami | Vaccine compositions and methods of use thereof |
| CN102475886A (zh) * | 2010-11-29 | 2012-05-30 | 南开大学 | 新型抗乳腺癌多肽疫苗 |
-
2014
- 2014-01-29 CA CA2840997A patent/CA2840997A1/en not_active Abandoned
- 2014-01-29 JP JP2014014804A patent/JP2014169278A/ja active Pending
- 2014-01-29 RU RU2014102938/10A patent/RU2014102938A/ru not_active Application Discontinuation
- 2014-01-29 US US14/166,952 patent/US20140220100A1/en not_active Abandoned
- 2014-01-29 CN CN201410043336.6A patent/CN103961696A/zh active Pending
- 2014-01-29 IN IN390CH2014 patent/IN2014CH00390A/en unknown
- 2014-01-29 KR KR1020140011625A patent/KR20140100415A/ko not_active Withdrawn
- 2014-01-29 EP EP14000323.7A patent/EP2762158A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN103961696A (zh) | 2014-08-06 |
| CA2840997A1 (en) | 2014-08-05 |
| EP2762158A1 (en) | 2014-08-06 |
| KR20140100415A (ko) | 2014-08-14 |
| US20140220100A1 (en) | 2014-08-07 |
| JP2014169278A (ja) | 2014-09-18 |
| IN2014CH00390A (enExample) | 2015-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014102940A (ru) | Композиция противораковой вакцины, содержащая пептид wt1, для трансдермального введения | |
| RU2014102937A (ru) | Препарат противораковой вакцины, содержащий пептид wt1, в форме ленты трансдермального введения | |
| RU2014102936A (ru) | Композиции противораковой вакцины, содержащей пептид wt1, для трансдермального введения | |
| RU2014102945A (ru) | Вакцинная композиция | |
| RU2014102946A (ru) | Вакцинная композиция против злокачественной опухоли на основе пептида wt1 для мукозального введения | |
| RU2014102944A (ru) | Композиция вакцины для трансдермального или трансмукозального введения | |
| BR112015029920A2 (pt) | sistema de administração transdérmica | |
| US10471140B2 (en) | Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition | |
| JP4847437B2 (ja) | アルカロイド製剤 | |
| CO2017003070A2 (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos | |
| JP6577795B2 (ja) | ビスホスホネート剤を含む細胞性免疫用ワクチン医薬組成物 | |
| RU2014102939A (ru) | Вакцинная композиция для чрескожного введения | |
| EP4218819A3 (en) | Combination therapy based on pd-1 signal inhibitors | |
| JP2011526889A (ja) | 局所局部的神経作用療法 | |
| MX2015002378A (es) | Composicion ansiolitica, formulacion y metodo de uso. | |
| WO2011157416A3 (de) | Transdermale verabreichung von memantin | |
| RU2014102948A (ru) | Вакцинная композиция для мукозального введения | |
| US10137079B2 (en) | Transdermal composition for treating pain | |
| CN102196820A (zh) | 用于治疗脑型疟的s1p受体激动剂 | |
| RU2019111096A (ru) | Лекарственные формы леводопы для быстрого купирования болезни паркинсона | |
| AR084093A1 (es) | Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica | |
| MX2019001032A (es) | Formulacion que tiene caracteristicas mejoradas de liberacion de farmacos ph dependientes, que contienen esomeprazol o una de sus sales farmaceuticas aceptable. | |
| EA201990668A1 (ru) | Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение | |
| Bartsch et al. | The ORL-1 (NOP1) receptor ligand nociceptin/orphanin FQ (N/OFQ) inhibits neurogenic dural vasodilatation in the rat | |
| WO2018164121A1 (ja) | 局所麻酔薬含有酸性エマルション組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180524 |